National Health Investors price target lowered to $85 from $87 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on National Health Investors (NHI) to $85 from $87 and keeps an Overweight rating on the shares. U.S. equity REITs returned 2.9% in 2025, lagging the S&P 500, but 2026 may offer optimism with a potentially more supportive macro environment and an accelerating M&A theme, the analyst tells investors in a research note. Stable supply and demand fundamentals, balance sheet strength, and a well-covered, growing 4% dividend yield make the sector attractive despite past underperformance, Cantor adds.